The Master of Biotechnology Program at Texas A&M University is a non-thesis, four-semester, cross-disciplinary program that leads to a Master of Biotechnology (MBIOT) degree. Depending on the business electives pursued, students completing the MBIOT degree are also eligible for a Certificate in Entrepreneurship from the Mays Business School. The program involves faculty from the College of Agriculture and Life Sciences, the College of Arts and Sciences, the Mays Business School, the College of Engineering, the School of Veterinary Medicine and Biomedical Sciences, and Health Science Center.
Our program goal is to produce high quality science managers for the biotechnology industry. MBIOT Program is intended for students who want graduate training with an industry orientation in the life sciences; the program emphasizes problem-solving and technical skills and involves study in business and science.
The Texas Higher Education Coordinating Board authorized Texas A&M University to implement the Master of Biotechnology (MBIOT) degree in April, 2001 and the first graduates received their diplomas later that year.
As of May 2023 there are 358 graduates of our program. MBIOT graduates are in high demand and work in a variety of fields, ranging from research and development of new drugs and medical devices to the manufacturing, sales and marketing of molecular biotechnology products and services. A few of our graduates have also elected to obtain PhD’s or pursue further education in law and medicine following completion of the MBIOT degree.
Our program goal is to produce high quality science managers for the biotechnology industry. MBIOT Program is intended for students who want graduate training with an industry orientation in the life sciences; the program emphasizes problem-solving and technical skills and involves study in business and science.
The Texas Higher Education Coordinating Board authorized Texas A&M University to implement the Master of Biotechnology (MBIOT) degree in April, 2001 and the first graduates received their diplomas later that year.
As of May 2023 there are 358 graduates of our program. MBIOT graduates are in high demand and work in a variety of fields, ranging from research and development of new drugs and medical devices to the manufacturing, sales and marketing of molecular biotechnology products and services. A few of our graduates have also elected to obtain PhD’s or pursue further education in law and medicine following completion of the MBIOT degree.